Boehringer Ingelheim Pharmaceuticals‘s Cyltezo, a second biosimilar for AbbVie’s Humira, received FDA approval.
AzurRx BioPharma enrolled a sixth patient into its phase IIa trial for MS1819, a treatment for exocrine pancreatic insufficiency associated with chronic pancreatitis.
4D Pharma is preparing to move its irritable bowel syndrome drug, Blautix, into a phase II clinical trial.
More articles on gastroenterology:
Stock market week-in-review for 5 large GI companies — Aug. 21-25
GI center to know: Associated Endoscopy
GI leader to know: Dr. G. Whit James of Associates in Gastroenterology
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
